Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy  by Ströbel, Philipp et al.
MALIGNANCIES OF THE THYMUS
Thymoma and Thymic Carcinoma
Molecular Pathology and Targeted Therapy
Philipp Stro¨bel, MD,* Peter Hohenberger, MD,† and Alexander Marx, MD*
Abstract: Thymomas and thymic carcinomas (TC) are rare epithe-
lial tumors of the thymus. Although most thymomas have organo-
typic features (i.e., resemble the normal thymus), TC are morpho-
logically undistinguishable from carcinomas in other organs. Apart
from their different morphology, TC and thymomas differ also in
functional terms (TC, in contrast to thymomas, have lost the capac-
ity to promote the maturation of intratumorous lymphocytes), have
different genetic features (discussed in this review), a different
immunoprofile (most TC overexpress c-KIT, whereas thymomas are
consistently negative), and different clinical features (TC, in contrast
to thymomas, are not associated with paraneoplastic myasthenia
gravis). Thus, although all the data suggest that the biology of
thymomas and TC is different, in clinical practice, their therapeutic
management up to now is identical. In the age of personalized
medicine, the time may have come to think this over. We will briefly
review the molecular genetics of malignant thymic tumors, summa-
rize the current status of targeted therapies with an emphasis on the
multitargeted kinase inhibitors sunitinib and sorafenib, and try to
outline some future directions.
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THYMOMA AND THYMIC CARCINOMA:
DEFINITIONS AND CLINICOPATHOLOGIC
FEATURES
Based on available current knowledge about the biol-
ogy of these tumors, the World Health Organization (WHO)
classification of thymic epithelial tumors1 separates thymo-
mas from thymic carcinomas.
Thymomas are defined as neoplasms arising from or
exhibiting differentiation toward thymic epithelial cells, usu-
ally with a variable component of non-neoplastic lympho-
cytes.1 From a morphologic point of view, there are two
major types of thymoma: in type A, the neoplastic epithelial
cells have a spindle- or oval-shaped nucleus with a uniform
bland cytology. In type B, the tumor cells have a predomi-
nantly round or polygonal appearance. Type B thymomas are
further subdivided depending on the degree of atypia and the
size of the lymphocyte component into B1 (richest in lym-
phocytes), B2, and B3 (richest in epithelial cells). Thymomas
combining type A with type B features are designated AB.
Apart from their different morphology, type A, AB, and B
thymomas also show differences with respect to molecular
genetics (see below), expression of immunohistochemical
markers, such as MHC class II or AIRE (autoimmune regu-
lator),2–4 a different capacity to promote maturation of intra-
tumoral lymphocytes,5,6 and different association with clini-
cal autoimmune syndromes, such as myasthenia gravis
(MG).7–10 Together with gene expression data, these findings
have led to the unifying hypothesis that the different histo-
logic thymoma subtypes may reflect different maturational
stages of a thymic epithelial progenitor cell.11
In most published series,9,12–14 the predominant histo-
logic subtypes are B2 and AB thymomas (each 20–35% of all
cases), whereas type B1 and type A thymomas count among
the rare types (5–10% in most studies). For clinical purposes,
thymomas can be stratified into two different risk groups:
type A, AB and B1 thymomas in most retrospective studies
pursued an indolent course with 5- and 10-year overall
survival rates between 80 and 100%.9,13,15 By contrast, type
B2 and B3 thymomas are potentially aggressive tumors with
a potential for distant metastases (approximately 15% of
cases),7–9,13,16 usually to lung, liver, bone, and soft tissues.
More frequently (up to 25% of cases in some series), these
tumors show pleural dissemination. Lymph node metastases
are exceedingly rare.17
Thymomas occur over a wide age range (Figure 1A)
but most manifest in the age between 50 and 60 years. In
our own series of about 1000 cases, thymomas before the
age of 30 years usually belonged to the clinical high-risk
group (Figure 1B).
Thymic carcinomas by definition1 are malignant epi-
thelial tumors with overt cytologic atypia, almost invariably
invasiveness and lack the “organotypic” (thymus-like) fea-
tures of thymomas. They are further subclassified into squa-
mous cell, basaloid, lymphoepithelioma-like, neuroendo-
crine, and many other types. Squamous cell carcinoma is the
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most frequent subtype with a higher incidence in Asia than in
western countries.9 The typical autoimmune phenomena seen
in thymoma (MG, pure red cell aplasia) are not found in
thymic carcinoma, although other paraneoplastic syndromes
such as polymyositis can occur. In contrast to thymomas,
thymic carcinomas may show metastasis to regional lymph
nodes (mediastinal, cervical, and axillary), although in our
experience this is still a rare event. They frequently express
CD117 (c-KIT),18,19 a helpful immunohistochemical feature,
to differentiate thymic carcinomas from mediastinal metasta-
ses of carcinomas located elsewhere.20
MOLECULAR GENETICS OF THYMOMAS AND
THYMIC CARCINOMAS
Molecular Genetics of Thymomas
The histologic thymoma subtypes listed in the WHO
classification show distinct molecular genetic features. In
summarizing a large body of data from CGH (comparative
genomic hybridization)21,22 and microsatellite/LOH (loss
of heterozygosity) studies,11,23,24 type A and AB thymomas
show a low frequency (7–8%) of allelic imbalances,
whereas type B2 and B3 thymomas show alterations in
approximately 20% of cases.11 However, if the percentage
of cases with multiple affected chromosomes is consid-
ered, type AB thymomas (55% of cases) are intermediate
between type A (10% of cases) and types B2 and B3
thymomas (75–100% of cases). Also, with respect to the
affected chromosomal regions, type AB thymomas show
overlap with both type A and type B thymomas but appear
more akin to the B type. In microdissected samples, the “A
component” in type AB thymomas was not genetically
identical to genuine A thymomas.11
In more detail, the most frequent genetic alterations in
all thymomas (and also in thymic squamous cell carcinomas)
affect chromosome 6p21.3 (MHC locus) and 6q25.2–
25.3.11,21,23 The identification of a common genetic alteration
on 6q25 across all histologic tumor subtypes suggests the
presence of a yet undefined common tumor suppressor (“gate
keeper”) gene that may eventually play a role in the biology
of the common thymic medullary/cortical progenitor cell.
The responsible genes have not been identified so far. Addi-
tional alterations that usually affect the aggressive subtypes
B2 and B3 are located on chromosome 5q21–22 (the APC
locus), chromosome 7p15.3, and chromosome 8p11.21. In-
terestingly, a few type AB thymomas also showed LOH of
the APC locus and the “high risk” alteration on chromosome
8p11.21, but this appeared not to be associated with a more
aggressive phenotype in these tumors, suggesting that these
high-risk mutations were counterbalanced by an unknown
tumor suppressor. Although type B2 and B3 show similar
genetic alterations, the combination of LOH of the APC, RB,
and TP53 locus has so far only been described in B3 thymo-
mas. An alternative oncogenic route to the “canonical path-
way” described above may be microsatellite instability that
has been found in a small percentage of thymomas (but so far
not in thymic carcinomas) (Figure 2).24
Molecular Genetics of Thymic Carcinomas
Thymic squamous cell carcinomas frequently show
gains of chromosomes 1q, 17q, and 18 and losses of chro-
mosomes 3p, 6, 16q, and 17p.21,22 Apart from the consistent
“thymic stemness” alteration on chromosome 6q25, they
share some similarities with type B3 thymomas, namely gain
of 1q and loss of chromosome 6, but overall, they are
genetically distinct from thymomas, justifying their listing as
a separate entity in the WHO classification. Of note, the
genetic alterations found in thymic squamous carcinomas of
the thymus are very distinctive, and the overlap with histo-
logically similar, “environmental” tumors of the lung, head,
and neck is minimal.22,25
THERAPEUTIC APPROACHES TO THYMOMA
AND THYMIC CARCINOMA
Chemotherapy-Based Multimodal Approaches
Although the treatment of malignant thymomas and
thymic carcinomas in daily clinical practice is identical, the
available data (see above) suggest that their biology is dif-
ferent and that in fact they may also require different thera-
peutic approaches. Advanced thymomas and TC that cannot
be completely resected require neoadjuvant or adjuvant sys-
temic treatment, often in combination with radiotherapy.26
Cisplatin-based regimens, such as the PAC scheme (cisplatin,
adriamycin, and cyclophosphamide) are most often used.27,28
Relapses or progressive disease can be expected to occur in
10 to 30% of all patients. In 20 to 30% of these patients,
objective remissions can be achieved by cisplatin-based reg-
FIGURE 1. A, Age distribution of thymomas
(n 815) and thymic carcinomas (n  128)
showing similar age peaks for the fifth to sixth
decade. B, In patients younger than 30 years at
primary diagnosis, most thymic epithelial tu-
mors belonged to the malignant categories.
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imens after relapse-free intervals. Approximately 50% of
patients with an advanced malignant thymoma or thymic
carcinoma will be candidates for a—so far undefined—
second-line treatment.
Interference with Receptor Tyrosine Kinases
(So-Called Targeted Approaches)
Targeted molecular therapy is a new paradigm in can-
cer treatment, where drugs selectively interfere with mole-
cules considered important in oncogenesis. While conven-
tional chemotherapy aims to kill off all proliferating cells
including tumors, molecularly targeted therapy aims to dis-
rupt cancer-specific signaling pathways involved in tumor
growth and proliferation.29 Compared with the toxicity of
chemotherapy, targeted molecular therapies seem relatively
tolerable.30 Tyrosine kinases regulate important cell functions
including survival, differentiation, and proliferation.29
Interference with Single Receptor Tyrosine
Kinases
c-KIT. A clinical response to imatinib in a thymic carci-
noma with a V560 mutation of c-KIT was previously de-
scribed.31 However, KIT is never expressed by malignant
thymomas and KIT mutations are rare (in the range of
10%),22,32 even in thymic carcinomas overexpressing KIT by
immunohistochemistry.22,32–34 Another case report mentioned
the unsuccessful last-resort use of imatinib in a pediatric
patient.35 These findings together with the disappointing re-
sults of two recent clinical phase II trials36,37 suggest that
imatinib will be a therapeutic option only for the small subset
of thymic carcinoma patients with KIT mutations.
EGFR. In theory, the epidermal growth factor receptor
(EGFR) is an attractive target in thymomas. Most malignant
thymomas and many thymic carcinomas show EGFR over-
expression by immunohistochemistry,18,38,39 and some ex-
hibit EGFR gene amplifications.39 Downstream mutations
that could interfere with EGFR antagonists, such as KRAS or
BRAF, are exceedingly rare.22 Although single case observa-
tions suggest that EGFR targeting may be effective in some
patients,40–42 two clinical phase II studies using erlotinib43
and gefitinib44 in a total of 44 patients resulted in no complete
remission and only two partial remissions. So far, there have
been no studies to directly compare the effect of monoclonal
antibodies (e.g., cetuximab) versus small molecule inhibitors.
It is not known whether the EGFR gene amplification status
influences the therapeutic response.
Interference with Multiple Receptor Tyrosine
Kinases
Sorafenib. In addition to multiple receptor tyrosine kinases,
such as PDGFR, c-KIT, and VEGFR, sorafenib also inhibits
wild-type and V600E-mutated Raf.45 One case report de-
scribed a patient with chemotherapy-resistant metastatic thy-
mic carcinoma, where administration of sorafenib led to
substantial tumor reduction by 4 months and stable disease
for another 5 months.46 To this, we can add the descriptions
of two patients with therapy-refractory type B3 thymomas
who were treated with sorafenib in our institution.
Case 1. A 56-year-old woman presented with histologi-
cally proven liver and chest wall metastases as a second
relapse of a type B3 thymoma 17 years after initial diagnosis
(then a Masaoka stage IVa tumor) and 7 years after the first
tumor relapse. The primary tumor had been treated by ex-
tended resection of the primary and pleural metastases, fol-
lowed by radiation therapy. The tumor was a classic c-KIT-
negative type B3 thymoma. Sequencing of EGFR, KRAS,
and BRAF was unremarkable. The patient was administered
two cycles of ACO (adriamycin, cyclophosphamide, and
cisplatin), later chlorambucil/dexamethasone, without obtain-
ing tumor control. Because of progressive disease with new
liver metastasis, the patient was given sunitinib for 2 months
but developed new lung metastases and progression of liver
foci. The patient then received experimental treatment with
sorafenib. A control PET scan after 8 weeks showed reduced
glucose uptake in all lesions. The patient had severe diarrhea
as side effect of her medication. Twenty-four weeks later, the
lung metastasis was still unchanged on CT scan, but glucose
uptake on PET was increased again and her liver metastases
FIGURE 2. Molecular genetic routes in thymomas and thy-
mic carcinomas. Genetic alterations of chr. 6q25 are found
in all entities, suggesting the presence of a “gatekeeper”
mutation in a common progenitor cell. Type AB, B2, and B3
thymomas show some genetic similarities with respect to
common alterations. Part of B3 thymomas may develop
along an alternative route, as indicated by the presence of
mutations within the APC, RB, and TP53 gene locus, which is
in good agreement with their slightly more aggressive be-
havior compared with type B2. Thymic carcinomas not only
show some genetic overlap with B3 thymomas, namely gain
of chromosome 1q and losses of chromosome 16q, but also
show additional recurrent alterations that are not found in
B3 thymomas.
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showed progression on both CT and PET scan, and sorafenib
was discontinued.
Case 2. A 44-year-old woman presented with a type B3
thymoma Masaoka stage III with infiltration of pleura and
lung in 1995. The tumor was completely resected and adju-
vant irradiation was applied. The patient suffered from para-
neoplastic MG, which was treated with azathioprine. Twelve
years later (2007), rising anti-acetylcholine receptor (AChR)
antibodies heralded a multifocal intrathoracal tumor relapse,
which was confirmed by histology and was treated by lung
lobectomy, pericardial resection, and resection of parts of the
diaphragm and of the right phrenic nerve. Despite ongoing
corticosteroid treatment after surgery, anti-AChR autoanti-
body titers continued to rise and myasthenic symptoms dete-
riorated. Under the suspicion of imminent thymoma relapse,
the patient received an experimental therapy with sorafenib
400 mg/d. An FDG-PET scan 5 months later showed two
preaortal and prehepatic hypermetabolic foci. The patient
developed massive hand-foot skin reactions but carried on
with sorafenib for 4 months. During that time, her anti-AChR
titers declined from 54 to 15 nmol/l. FDG-PET revealed
slightly reduced uptake of the preaortal lesion, whereas up-
take of the prehepatic focus was unchanged.
In summary, the available evidence is very preliminary but
suggests that sorafenib could be biologically active in some
malignant thymomas and thymic carcinomas and may merit
further clinical study. It seems that different metastatic le-
sions in one patient may be heterogeneous and may show a
mixed response to such targeted (and “conventional” chemo-
therapeutic) treatments.
Sunitinib. Sunitinib is a multitarget tyrosine kinase inhibitor
that was designed to block intracellular receptor binding sites
of several tyrosine kinases including vascular endothelial
growth factors 1–3 (VEGF1–3), FMS-like tyrosine kinase 3
(FLT3), stem cell growth factor (c-KIT), platelet-derived
growth factors  and  (PDGF-), colony-stimulating fac-
tor 1 (CSF1), and the “RET” receptor for glial-derived neu-
rotrophic factors.47 Inhibition through sunitinib is believed to
ultimately result in tumor regression through antiangiogenic
effects and also through direct tumor cell apoptosis.
We have recently described initial clinical experience with
sunitinib in four patients with advanced thymic carcinomas
refractory to conventional therapies.48 Administration of
sunitinib was based on the observation that these tumors
showed simultaneous activation of several receptor tyrosine
kinases, including the EGFR, TYRO3, insulin receptor, and
insulin-like growth factor-1 receptor (IGF1R). Administra-
tion of sunitinib yielded a partial remission (lasting 2–18
months) according to RECIST49 in three patients and stable
disease with excellent metabolic response in 18F-FDG-PET
in another one patient. Overall survival with sunitinib treat-
ment ranged from 4 to 40 months. Withdrawal of the drug
in one patient prompted rapid tumor progression that could be
controlled by readministration of sunitinib. The latter obser-
vation provides very strong circumstantial evidence that
sunitinib was able to control the patient’s tumor over more
than 3 years and even at relapse of sunitinib-pretreated
metastases. Similar favorable findings in two other patients
with long-term stable remissions indicate that sunitinib may
be able to block tumor escape mechanisms in at least some
thymic carcinomas and may be a promising option for long-
term treatment. At this moment, the exact mode of action of
sunitinib in thymic carcinomas is not clear. There were no
mutations of c-KIT (exons 9, 11, 13, and 17), KRAS, BRAF,
or EGFR, so apparently the effectiveness of sunitinib does
not depend on such abnormalities. Interestingly, Girard et al.
recently described a novel H697Y c-KIT mutation in exon 14
(which had not been sequenced in our study) in a thymic
carcinoma, which conferred sensitivity to sunitinib when
transfected into a cell line. It will be important to determine
the frequency of this mutation in a larger case series. How-
ever, c-KIT was not strongly activated in a sensitive phos-
phoblot assay in our sunitinib-responsive clinical cases and
thus was an unlikely prime target. Based on published data,50
it is conceivable that sunitinib’s predominant mechanism of
action was antiangiogenesis, even though its main known
targets (e.g., the VEGFRs) were not prominently activated in
the tumor samples studied in our series. Further clinical
studies will be needed to analyze the underlying mechanisms
more thoroughly to determine whether the respective targets
are also present in malignant thymomas and to establish
biomarkers to predict therapeutic response to sunitinib.
CONCLUDING REMARKS
In summary, all available data to date indicate that
thymoma and thymic carcinoma are distinct entities that may
require different therapeutic approaches in the near future,
despite the fact that this would mean just another obstacle in
clinical research by further decreasing case numbers. Never-
theless, emerging gene expression and sequencing data point
to the fact that there is probably considerable heterogeneity
even among tumors of the same histotype. In the age of
personalized medicine, international efforts are mandatory to
overcome these new limitations and to finally advance the
treatment of thymomas and thymic carcinomas.
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